| Literature DB >> 31807218 |
Hoang Huy Do1,2, Saif Ullah3, Alexander Villinger1, Joanna Lecka4,5, Jean Sévigny4,5, Peter Ehlers1,6, Jamshed Iqbal3, Peter Langer1,6.
Abstract
A two-step palladium-catalyzed procedure based on Suzuki-Miyaura cross coupling, followed by a double Buchwald-Hartwig reaction, allows for the synthesis of pharmaceutically relevant benzo[4,5]furo[3,2-b]indoles in moderate to very good yield. The synthesized compounds have been analyzed with regard to their inhibitory activity (IC50) of nucleotide pyrophosphatases h-NPP1 and h-NPP3. The activity lies in the nanomolar range. The results were rationalized based on docking studies.Entities:
Keywords: Buchwald–Hartwig reaction; N-heterocycles; Suzuki–Miyaura reaction; cyclization; palladium
Year: 2019 PMID: 31807218 PMCID: PMC6880817 DOI: 10.3762/bjoc.15.276
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.883
Figure 1Pharmacologically relevant furoindoles.
Scheme 1Synthesis of benzo[4,5]furo[3,2-b]indoles 5a–j. Conditions: (i) 1.2 equiv 2-bromophenylboronic acid (2), 5 mol % Pd(PPh3)4, 3.0 equiv K3PO4, 1,4-dioxane, H2O, 100 ºC, 8 h. (ii) 1.5 equiv 4, 3.0 equiv NaOt-Bu, 5 mol % Pd2(dba)3, 10 mol % ligand, toluene, 110 ºC, 12 h.
Optimization for the Synthesis of 5b.
| Entry | Pd precursor | Ligand | Yield (%)a |
| Pd2(dba)3 | dppf | 57 | |
| Pd2(dba)3 | XantPhos | 54 | |
| Pd2(dba)3 | dppe | 62 | |
| Pd2(dba)3 | BINAP | 75 | |
| Pd2(dba)3 | XPhos | 36 | |
| Pd2(dba)3 | SPhos | 44 | |
| Pd2(dba)3 | DavePhos | 15 | |
| Pd2(dba)3 | RuPhos | 45 | |
| Pd2(dba)3 | P | 41 | |
| Pd(OAc)2 | BINAP | 52 | |
| Pd2(dba)3 | BINAP | 61 | |
| Pd2(dba)3 | BINAP | 14 | |
aYield calculated by 1H NMR of the crude product using 1,4-dioxane as an internal standard. bDioxane. cDMF.
Synthesis of 5a–ja.
| R | Yield (%)b | |
| Ph | 63 | |
| 4-MeC6H4 | 75 | |
| 4-FC6H4 | 79 | |
| 3-(CF3)C6H4 | 81 | |
| 4-(MeO)C6H4 | 65 | |
| 3,4-(MeO)2C6H3 | 51 | |
| 4- | 84 | |
| Bn | 67c | |
| 53c | ||
| Cyclohexyl | 57c | |
aConditions: 1.5 equiv amine 4, 3.0 equiv NaOt-Bu, 5 mol % Pd2(dba)3, 10 mol % ligand, toluene, 110 ºC, 12 h; bIsolated yields; cDavePhos as ligand.
Figure 2Ortep of 5c (propability of ellipsoids: 45%).
Figure 3Diindolofurans 6a–e.
Biological activity of 5 and 6.
| – | 1.38 ± 0.03 | |
| 2.84 ± 0.06 | 0.59 ± 0.02 | |
| 1.29 ± 0.07 | 3.14 ± 0.09 | |
| 3.57 ± 0.03 | 0.49 ± 0.04 | |
| – | 0.26 ± 0.01 | |
| 2.62 ± 0.03 | 0.27 ± 0.06 | |
| 3.27 ± 0.08 | 2.55 ± 0.07 | |
| 6.14 ± 0.09 | 2.39 ± 0.05 | |
| 0.11 ± 0.06 | 0.61 ± 0.09 | |
| – | 0.13 ± 0.06 | |
| – | 0.28 ± 0.04 | |
| 1.38 ± 0.09 | 0.18 ± 0.01 | |
| 0.53 ± 0.09 | 0.21 ± 0.04 | |
aThe IC50 is the concentration at which 50% of the enzyme activity is inhibited.
Figure 4Illustration of binding poses of selected inhibitors for the ENPP1 homology model: (a): suramin, (b): 5c, (c): 6a, (d): 6e.
Figure 53D poses of docked selected inhibitors inside homology model of ENPP3. (a): suramin, (b): 5e, (c): 5h, (d): 6e.